Global Human Growth Hormone Market by Application (Turner Syndrome, Growth Hormone Deficiency) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Summary of the Report
Global human growth hormone market was valued at USD4.6 billion in 2019. It is expected to grow 8.2% during the forecast period. Market drivers include strong R&D, strong product portfolios, investments by market players, and increased government initiatives.
The peptide hormone human growth hormone (HGH), also called somatotropin and responsible for cell reproduction and growth stimulation in humans, is essential for human development. A pituitary gland that does not produce enough hGH can cause growth hormone (GH) deficiencies in humans. Subcutaneous injections of recombinant human Growth Hormone can treat this deficiency. Prader-Willi Syndrome and Turner syndrome may also lead to growth hormone deficiency. This can cause delayed puberty, shorter height, and other genetic conditions.
The American Academy of Pediatrics published data showing that growth hormone deficiency in humans is rare and affects less then one in 3,000 to one million children in the United States. Currently, hGH is widely abused as an anti-aging treatment in older adults and as a performance-enhancing anabolic drug by bodybuilders and athletes. However, HGH is a controlled substance as per the USFDA and has not been approved for anti-aging and performance-enhancing indications.
Market for human growth hormones will be driven by a strong product pipeline and extensive R&D activities to develop novel therapies. Novo Nordisk, for example, presented Phase II data from its investigational GH therapy Somapacitan in September 2018. This is indicated for the treatment and prevention of growth hormone deficiency. Ascendis Pharma A/S also published Phase III results from its TransCon HGH clinical trial, which was indicated for the treatment of pediatric growth hormone deficiencies. Several key players, including Teva Pharmaceutical Industries, Ltd., OPKO Health, Inc., Eli Lilly and Company, Ferring Pharmaceuticals, Sanofi S.A., and LG Life Sciences, are also involved in R&D activities to develop novel human growth hormone therapies.
The market will be driven by initiatives taken by both government and private organizations to raise awareness about GH deficiencies as well as human growth hormone treatment. The International Coalition of Organizations Supporting Endocrinine Patients (ICOSEP), a U.S.-based non-profit charitable organization, celebrates International Children's Growth Awareness Day every year to raise awareness about early diagnosis and treatment of growthhormone disorders in children.
The market's progress may be impeded by the high cost of hGH treatments and other adverse effects. According to UPMC Children's Hospital of Pittsburgh (UPMC Children's Hospital of Pittsburgh), side effects of GH hormone therapy could include joint pain, swelling or hives, and knee or hip pain.
Application Insights
The GH deficiency segment dominated the market in 2019 and will continue to dominate the market over the forecast period. This is due to increased awareness regarding early diagnosis and treatment for GH deficiency in people and the introduction novel drugs into the hGH market. Ascendis Pharma A/S was granted Orphan Designation by the European Commission (EC), in October 2018 for TransCon hGH, an investigational long-acting GH treatment for humans. This is indicated for treating pediatric GH deficiency.
Ferring Pharmaceuticals Inc. was also approved by the USFDA in January 2018 for Zomacton (somatropin), a recombinant HGH that is indicated for treatment of adults suffering from GH deficiency. Due to increasing supply of pipeline drugs, the market for GH deficiency is further divided into two segments: pediatric GH and adult GH. In October 2019, Pfizer Inc., along with its partner OPKO Health Inc., announced that the Phase III study on Somatrogon in prepubertal children with hGH had met its primary endpoint. It was non-inferior to daily somatropin.
Turner's syndrome was the second-largest segment in the 2019 market and will continue to grow as a profitable market over the forecast period. This is due to the increasing awareness of Turner syndrome by both public and private organizations. Turner Syndrome Society of the United States (UK), Turner Syndrome Society of the United States (USA) and Turner Syndrome Foundation organize "Turner Syndrome Awareness Month" each February to raise awareness and create a national campaign.
Distribution Channel Insights
The distribution channel is what separates the market for human growth hormone into specialty pharmacy, online pharmacy and retail pharmacy. In 2019, the hospital pharmacy segment accounted for a large share. The hospital pharmacy segment accounted for a significant share of 2019's total. This is due to an increase in hospital visits and awareness about GH deficiencies among people and treatment. According to the Children's Hospital of Philadelphia, prescriptions for growth hormone have increased from 5.1 per 10,000 beneficiaries in 2001 up to 14.6 per 10,000 in 2016.
Due to the high penetration in pharmacies in developed countries like North America and Europe, the online pharmacy segment will see a significant CAGR during the forecast period. The segment will continue to grow due to the rising popularity of online pharmacies within emerging economies like India and China.
Regional Insights
North America accounts for the largest percentage of global healthcare spending. This is due to factors like a favorable reimbursement system, established healthcare infrastructure, substantial government initiatives and increasing healthcare awareness. The North American market is supported by the presence of key players. Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc., are key U.S. players offering a broad range of human GH treatments in the region.
The Asia Pacific region is expected to experience a substantial CAGR during the forecast period. The key players are focused on gaining market share in the potential Asian countries such as Japan, China and South Korea by gaining approvals and launching new products. Novo Nordisk A/S, an American pharmaceutical company based in Denmark, began the third phase of its HGH somapacitan clinical trial in Japan in March 2017.
Market Share in Human Growth Hormones
Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Sandoz International GmbH, (Novartis AG); Merck KGaA, Genentech, Inc., (Roche); Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd., and Ipsen are some of the major players in this market. Many companies are focused on long-acting hormones for human growth.
Major companies in the market are using mergers, partnerships and acquisitions to increase their geographical reach and access to their solutions. Novo Nordisk and Strongbridge Biopharma, for example, signed an agreement in October 2018 to acquire rights to MACRILEN in Canada and the U.S. MACRILEN (macimorelin), the FDA's first and only approved oral drug for adult growth hormone deficiencies diagnosis, is MACRILEN.
Human Growth Hormones Market Report Scope
Report Attribute |
More Details |
2020 Market Size Value |
USD 3.7 Billion |
Forecast Revenues in 2027 |
USD 8.5 Billion |
Growth Rate |
CAGR of 8.2% between 2020 and 2027 |
Estimation base year |
2019 |
Historical data |
2016-2018 |
Forecast period |
2020-2027 |
Quantitative units |
From 2020 to 2027, revenue in USD million and CAGR |
Report coverage |
Forecast revenue; company share; competitive landscape, growth factors and trends |
Segments covered |
Application, distribution channel, and region |
Regional scope |
North America; Europe; Asia Pacific, Latin America; MEA |
Country coverage |
U.S.; Canada; U.K.; Germany; Spain; France; Italy; Russia; Japan; India; China; South Korea; Singapore; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE |
Key companies profiled |
Novo Nordisk A/S, Pfizer, Inc, Eli Lilly and Company, Sandoz International GmbH, (Novartis AG); Merck KGaA, Genentech, Inc, Roche; Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, Ipsen. |
The scope of customization |
With purchase, you get a free report customization (equivalent to up to 8 analysts working day) You can add or modify country, regional and segment scope. |
Prices and purchase options |
You can get customized purchase options that meet your research needs. Explore your purchase options |
The Report Covers Certain Segments
This report forecasts revenue growth at the global, regional and country level. It also provides analysis of industry trends and potential opportunities in each sub-segment from 2016-2027. Grand View Research has divided the global market for human growth hormones on the basis, of distribution channel and of region.
-
App Outlook (Revenue USD Million, 2016-2027)
-
Growth Hormone (GH) Deficiency
-
Adult GH Deficiency
-
Pediatric GH Deficiency
-
-
Turner Syndrome
-
Idiopathic Short Stature
-
Prader-Willi Syndrome
-
Gestational Age: Small
-
Other
-
-
Distribution Channel Outlook (Revenue USD Million, 2016-2027)
-
Hospital Pharmacy
-
Retail Pharmacy
-
Online pharmacy
-
Specialty Pharmacy
-
-
Regional Outlook (Revenue USD Million, 2016-2027)
-
North America
-
The U.S.
-
Canada
-
-
Europe
-
Germany
-
The U.K.
-
Spain
-
France
-
Italy
-
Russia
-
-
Asia Pacific
-
Japan
-
China
-
India
-
South Korea
-
Singapore
-
Australia
-
-
Latin America
-
Brazil
-
Mexico
-
Argentina
-
-
MEA
-
South Africa
-
Saudi Arabia
-
UAE
-
-
These are the most frequently asked questions about this report
What is the market for human growth hormones?b. Global human growth hormone market was valued at USD 3.6 billion in 2019, and is forecast to grow to USD 3.7 billion by 2020.
What is the market growth for human growth hormone?b. Global human growth hormone markets are expected to grow at 8.2% per year between 2020 and 2027, reaching USD 8.5 billion in 2027.
Which market segment had the largest share of human growth hormones?b. With a 35.9% share in 2019, North America dominated global human growth hormone markets. This can be attributed to factors like favorable reimbursement, established healthcare infrastructure, significant government initiative, and growing healthcare awareness.
Which companies are key players in the human growth hormone market?b. Novo Nordisk A/S, Pfizer, Inc, Eli Lilly and Company, Sandoz International GmbH, Novartis AG; Merck KGaA, Genentech, Inc (Roche), Ferring Pharmaceuticals, Teva Pharmaceutical Industries, Ltd, and Ipsen are some of the major players in the human growthhormone market.
What are the main factors that drive the market for human growth hormone?b. b.
Up Market Research published a new report titled “Human Growth Hormone Market research report which is segmented by Application (Turner Syndrome, Growth Hormone Deficiency), By Players/Companies Novo Nordisk A/S; Pfizer, Ltd; and Ipsen, Inc; Eli Lilly and Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech, Inc (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
Report Attributes | Report Details |
Report Title | Human Growth Hormone Market Research Report |
By Application | Turner Syndrome, Growth Hormone Deficiency |
By Companies | Novo Nordisk A/S; Pfizer, Ltd; and Ipsen, Inc; Eli Lilly and Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech, Inc (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries |
Regions Covered | North America, Europe, APAC, Latin America, MEA |
Base Year | 2020 |
Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
Forecast Year | 2028 |
Number of Pages | 200 |
Number of Tables & Figures | 140 |
Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Human Growth Hormone Market Report Segments:
The market is segmented by Application (Turner Syndrome, Growth Hormone Deficiency).
Human Growth Hormone Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Human Growth Hormone Market
Overview of the regional outlook of the Human Growth Hormone Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Human Growth Hormone Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Human Growth Hormone Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Turner Syndrome
2. Growth Hormone Deficiency
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Human Growth Hormone Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Human Growth Hormone Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Human Growth Hormone Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Human Growth Hormone Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Human Growth Hormone Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Human Growth Hormone Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Human Growth Hormone Market Size & Forecast, 2018-2028
4.5.1 Human Growth Hormone Market Size and Y-o-Y Growth
4.5.2 Human Growth Hormone Market Absolute $ Opportunity
Chapter 5 Global Human Growth Hormone Market Analysis and Forecast by Application
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Application
5.1.2 Basis Point Share (BPS) Analysis by Application
5.1.3 Absolute $ Opportunity Assessment by Application
5.2 Human Growth Hormone Market Size Forecast by Application
5.2.1 Turner Syndrome
5.2.2 Growth Hormone Deficiency
5.3 Market Attractiveness Analysis by Application
Chapter 6 Global Human Growth Hormone Market Analysis and Forecast by Region
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Region
6.1.2 Basis Point Share (BPS) Analysis by Region
6.1.3 Absolute $ Opportunity Assessment by Region
6.2 Human Growth Hormone Market Size Forecast by Region
6.2.1 North America
6.2.2 Europe
6.2.3 Asia Pacific
6.2.4 Latin America
6.2.5 Middle East & Africa (MEA)
6.3 Market Attractiveness Analysis by Region
Chapter 7 Coronavirus Disease (COVID-19) Impact
7.1 Introduction
7.2 Current & Future Impact Analysis
7.3 Economic Impact Analysis
7.4 Government Policies
7.5 Investment Scenario
Chapter 8 North America Human Growth Hormone Analysis and Forecast
8.1 Introduction
8.2 North America Human Growth Hormone Market Size Forecast by Country
8.2.1 U.S.
8.2.2 Canada
8.3 Basis Point Share (BPS) Analysis by Country
8.4 Absolute $ Opportunity Assessment by Country
8.5 Market Attractiveness Analysis by Country
8.6 North America Human Growth Hormone Market Size Forecast by Application
8.6.1 Turner Syndrome
8.6.2 Growth Hormone Deficiency
8.7 Basis Point Share (BPS) Analysis by Application
8.8 Absolute $ Opportunity Assessment by Application
8.9 Market Attractiveness Analysis by Application
Chapter 9 Europe Human Growth Hormone Analysis and Forecast
9.1 Introduction
9.2 Europe Human Growth Hormone Market Size Forecast by Country
9.2.1 Germany
9.2.2 France
9.2.3 Italy
9.2.4 U.K.
9.2.5 Spain
9.2.6 Russia
9.2.7 Rest of Europe
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 Europe Human Growth Hormone Market Size Forecast by Application
9.6.1 Turner Syndrome
9.6.2 Growth Hormone Deficiency
9.7 Basis Point Share (BPS) Analysis by Application
9.8 Absolute $ Opportunity Assessment by Application
9.9 Market Attractiveness Analysis by Application
Chapter 10 Asia Pacific Human Growth Hormone Analysis and Forecast
10.1 Introduction
10.2 Asia Pacific Human Growth Hormone Market Size Forecast by Country
10.2.1 China
10.2.2 Japan
10.2.3 South Korea
10.2.4 India
10.2.5 Australia
10.2.6 South East Asia (SEA)
10.2.7 Rest of Asia Pacific (APAC)
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Asia Pacific Human Growth Hormone Market Size Forecast by Application
10.6.1 Turner Syndrome
10.6.2 Growth Hormone Deficiency
10.7 Basis Point Share (BPS) Analysis by Application
10.8 Absolute $ Opportunity Assessment by Application
10.9 Market Attractiveness Analysis by Application
Chapter 11 Latin America Human Growth Hormone Analysis and Forecast
11.1 Introduction
11.2 Latin America Human Growth Hormone Market Size Forecast by Country
11.2.1 Brazil
11.2.2 Mexico
11.2.3 Rest of Latin America (LATAM)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Latin America Human Growth Hormone Market Size Forecast by Application
11.6.1 Turner Syndrome
11.6.2 Growth Hormone Deficiency
11.7 Basis Point Share (BPS) Analysis by Application
11.8 Absolute $ Opportunity Assessment by Application
11.9 Market Attractiveness Analysis by Application
Chapter 12 Middle East & Africa (MEA) Human Growth Hormone Analysis and Forecast
12.1 Introduction
12.2 Middle East & Africa (MEA) Human Growth Hormone Market Size Forecast by Country
12.2.1 Saudi Arabia
12.2.2 South Africa
12.2.3 UAE
12.2.4 Rest of Middle East & Africa (MEA)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Middle East & Africa (MEA) Human Growth Hormone Market Size Forecast by Application
12.6.1 Turner Syndrome
12.6.2 Growth Hormone Deficiency
12.7 Basis Point Share (BPS) Analysis by Application
12.8 Absolute $ Opportunity Assessment by Application
12.9 Market Attractiveness Analysis by Application
Chapter 13 Competition Landscape
13.1 Human Growth Hormone Market: Competitive Dashboard
13.2 Global Human Growth Hormone Market: Market Share Analysis, 2019
13.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
13.3.1 Novo Nordisk A/S; Pfizer
13.3.2 Ltd; and Ipsen
13.3.3 Inc; Eli Lilly and Company; Sandoz International GmbH (Novartis AG); Merck KGaA; Genentech
13.3.4 Inc (Roche); Ferring Pharmaceuticals; Teva Pharmaceutical Industries